tim duduit

Robert, I am not BRAF+. My oncologist suggested the trial because the tumor is in a lymph node between the adrenal gland and my spine.  Surgery would be major and would leave me waiting for the next tumor.  The genetic analysis of my tumor showed that my tumor is positive for the CDKN2A and ATK3 mutations and would be suseptible to CDK4/6 inhibitors and AKT inhibitors.  So I began the trial for the CDK inhibitor last thursday using the drug Tarceva (currently approved for use in a certain type of lung and pancreatic cancer).  I take the drug orally morning and evening and I will take it for 8 weeks and then have a PET scan to see if the tumor responded.  If the tumor shirnks or stays the same size, I will continue to take the drug because there is a benefit.  If it has gotten bigger, then we will talk about switching me to the AKT inhibitor.  The study is funded by Eli Lily and there is no time limit as long as I'm recieving a benefit from one of the two drugs.  No side effects yet.  Good luck with your tumor, too.

Robert, I am not BRAF+. My oncologist suggested the trial because the tumor is in a lymph node between the adrenal gland and my spine.  Surgery would be major and would leave me waiting for the next tumor.  The genetic analysis of my tumor showed that my tumor is positive for the CDKN2A and ATK3 mutations and would be suseptible to CDK4/6 inhibitors and AKT inhibitors.  So I began the trial for the CDK inhibitor last thursday using the drug Tarceva (currently approved for use in a certain type of lung and pancreatic cancer).  I take the drug orally morning and evening and I will take it for 8 weeks and then have a PET scan to see if the tumor responded.  If the tumor shirnks or stays the same size, I will continue to take the drug because there is a benefit.  If it has gotten bigger, then we will talk about switching me to the AKT inhibitor.  The study is funded by Eli Lily and there is no time limit as long as I'm recieving a benefit from one of the two drugs.  No side effects yet.  Good luck with your tumor, too.

Robert, I am not BRAF+. My oncologist suggested the trial because the tumor is in a lymph node between the adrenal gland and my spine.  Surgery would be major and would leave me waiting for the next tumor.  The genetic analysis of my tumor showed that my tumor is positive for the CDKN2A and ATK3 mutations and would be suseptible to CDK4/6 inhibitors and AKT inhibitors.  So I began the trial for the CDK inhibitor last thursday using the drug Tarceva (currently approved for use in a certain type of lung and pancreatic cancer).  I take the drug orally morning and evening and I will take it for 8 weeks and then have a PET scan to see if the tumor responded.  If the tumor shirnks or stays the same size, I will continue to take the drug because there is a benefit.  If it has gotten bigger, then we will talk about switching me to the AKT inhibitor.  The study is funded by Eli Lily and there is no time limit as long as I'm recieving a benefit from one of the two drugs.  No side effects yet.  Good luck with your tumor, too.

It is a study funded by Eli Lily Company and is being administered by the START cancer center here in San Antonio.

It is a study funded by Eli Lily Company and is being administered by the START cancer center here in San Antonio.

It is a study funded by Eli Lily Company and is being administered by the START cancer center here in San Antonio.